Brivanib response in endometrial organoids and cell lines
Cell-based study · REME9 and REME16 endometrial cancer patient-derived organoids; AN3 CA and RL95-2 endometrial cancer cell lines [1]
One comparative drug-screen design, represented once across all four models. Figure 6 shows the highest brivanib growth-response AUC in RL95-2, indicating a weaker inhibitory response than in the other plotted models; this is a qualitative visual comparison, without numerical bar extraction.
| Endpoint | Reported result | Reference |
|---|---|---|
| Area under the ATP-based growth-response curve, qualitatively compared across the four model columns | Growth-response AUC (qualitative) RL95-2 > REME9, REME16 and AN3 CA (visual comparison; exact AUC values not extracted) | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Serial concentrations up to 20 µM; lower-bound discrepancy retained in missing information.
- Exposure duration
- 144 h after treatment in the shared 384-well assay methods
- Method
- Single-agent comparative growth-response screen in 384-well plates
- Vehicle
- DMSO vehicle control; shared assay methods specify maximum 0.1%.
- Reported limits
- Methods specify ten concentrations from 1.0 nM to 20 µM; Figure 6 caption instead states 0.1–20 µM. The lower bound is unresolved and omitted from public interpretation. Exact model-specific AUC values, raw replicate data, lot number and stereochemical verification are not supplied in the reviewed locations.
Methods and source locations
Compound reported in the paper: Brivanib; Compound label in the paper: Brivanib (Table II)
Response of the material named brivanib in this experiment only; no alaninate conversion or quantitative kinase potency inference.
Figure 6 (brivanib row, all four model columns); Table II (Brivanib row); Materials and methods: Compounds, Cell culture, Growth inhibition assays using multi-well plates
Area under the ATP-based growth-response curve, qualitatively compared across the four model columns: CellTiter-Glo 3D ATP readout; response normalized to vehicle control after background subtraction; AUC calculated with Morphit 5.0. Figure 6 reports means of triplicate experiments; no error bars or between-model statistical test shown. — Figure 6, brivanib row and caption; Growth inhibition assays using multi-well plates